Diamonds and Dogs


ImmunoGen, Inc. (IMGN)

ImmunoGen spiked up 66% to $15.00 midday today after the company made an announcement at the American Society of Clinical Oncology conference. The company saw positive results from its ovarian cancer treatment, IMGN853. These Phase 1 results have led to a shift in Wall Street recommendations. Morgan Stanley upgraded the company to "Equal-weight" and John Newman raised his price target to $20. IMGN has now more than doubled year-to-date and is making big moves in healthcare.


Puma Biotechnology (PBYI

Puma Biotechnology did not see the same results in its cancer treatment. Neratinib, Puma's breast cancer treatment drug, did not have much of an effect on breast cancer patients, and the benefits were considered "awfully small." Puma's stock price dropped more than 10% and continues to slump as investors are losing confidence in the biotech's future and worried about the side effects of Neratinib. Even though the stock is still far above it's 52 week high at $175, today's results could foreshadow the company's future.  

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.